Volume | 1,823 |
|
|||||
News | - | ||||||
Day High | 3.16 | Low High |
|||||
Day Low | 3.0325 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NeuroBo Pharmaceuticals Inc | NRBO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.05 | 3.0325 | 3.16 | 3.06 | 3.10 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
54 | 1,823 | $ 3.12 | $ 5,680 | - | 2.8888 - 6.7499 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:21:45 | 10 | $ 3.06 | USD |
NeuroBo Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
15.04M | 4.85M | - | 0 | -12.47M | -2.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NeuroBo Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRBO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.63 | 3.63 | 2.99 | 3.17 | 29,659 | -0.57 | -15.70% |
1 Month | 4.24 | 4.39 | 2.99 | 3.59 | 27,350 | -1.18 | -27.83% |
3 Months | 3.96 | 6.7499 | 2.99 | 5.43 | 1,437,243 | -0.90 | -22.73% |
6 Months | 3.456 | 6.7499 | 2.90 | 5.32 | 708,911 | -0.396 | -11.46% |
1 Year | 5.36 | 6.7499 | 2.8888 | 5.01 | 500,167 | -2.30 | -42.91% |
3 Years | 849.60 | 1,576.80 | 2.8888 | 253.14 | 1,070,798 | -846.54 | -99.64% |
5 Years | 2,196.00 | 7,200.00 | 2.8888 | 312.96 | 775,830 | -2,192.94 | -99.86% |
NeuroBo Pharmaceuticals Description
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. |